Use fundamental data analysis to double-check all available reported financial drivers of BioShares Biotechnology to find out if markets are presently mispricing the etf. We found ten available fundamental indicators for BioShares Biotechnology Clinical Trials which can be compared to its rivals. Please makes use of BioShares Biotechnology Number of Employees as well as the relationship between One Year Return and Net Asset to make a decision on weather BioShares Biotechnology is priced fairly. Use BioShares Biotechnology to protect against small markets fluctuations. The etf experiences unexpected downward movement. The market is reacting to new fundamentals. Check odds of BioShares Biotechnology to be traded at $28.66 in 30 days
BioShares Biotechnology Company SummaryBioShares Biotechnology competes with Health Care, iShares Nasdaq, Vanguard Health, SPDR SP, and ISHARE DJ. The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80 percent of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. The fund is non-diversified.
BioShares Biotechnology Price to Earning vs Price to Book
BioShares Biotechnology Clinical Trials is second largest ETF in price to earning as compared to similar ETFs. It is rated below average in price to book as compared to similar ETFs fabricating about 0.04 of Price to Book per Price to Earning. The ratio of Price to Earning to Price to Book for BioShares Biotechnology Clinical Trials is roughly 22.78